Company Ka Revenue Toofani Tezi Se Badha! **30%** Jump, **Egypt** Plant Se Karega Duniya Jeetne Ki Taiyari?

CHEMICALS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Company Ka Revenue Toofani Tezi Se Badha! **30%** Jump, **Egypt** Plant Se Karega Duniya Jeetne Ki Taiyari?
Overview

Arre bhaiyo aur behno, suno! Company ne is baar Q3 mein kamaal kar diya hai. Standalone revenue mein **30.8%** ka zabardast YoY jump dikhaya hai, jo ab **₹102.6 Crore** ho gaya hai! Future ke liye toh **35%** ka CAGR target set kiya hai aur **Egypt** mein naya plant bhi aa raha hai!

Numbers Ka Khel: Q3 FY26 Mein Kya Hua?

Standalone revenue for Q3 FY26 pahuncha ₹102.6 Crore (₹1026.2 Million) par, jo pichhle saal se 30.8% zyada hai (₹78.5 Crore tha). Ekdum badiya growth!

Standalone EBITDA bhi 22.0% badh kar ₹16.3 Crore (₹162.5 Million) ho gaya.

Haan, ek cheez note karni padegi, standalone EBITDA margin thoda 120 basis points neeche gir kar 15.8% ho gaya hai (pehle 17.0% tha). PAT margin thoda theek hai, 12.6% par.

Consolidated side par, revenue 12.7% badh kar ₹104.7 Crore (₹1046.7 Million) hua. EBITDA 7.0% badh kar ₹15.8 Crore (₹157.9 Million) aur PAT 12.0% badh kar ₹12.3 Crore (₹123.3 Million) ho gaya. Consolidated EBITDA margin 15.1% par lagbhag stable raha.

9-month period (9M FY26) ki agar baat karein, toh standalone revenue 24.6% badha (₹302.4 Crore), lekin EBITDA 4.8% aur PAT 11.6% neeche gira. Consolidated mein bhi same trend: revenue up, EBITDA/PAT down.

Company Ki Pocket Mein Kitna Hai?

Ye CWIP (Capital Work in Progress) dekh rahe ho? Standalone ₹43.4 Crore aur consolidated ₹43.8 Crore ho gaya hai, jo FY24 mein sirf ₹7.7 Crore tha. Ye dikhata hai ki company bade expansion projects par paisa laga rahi hai.

Sabse achhi baat, company par loan lagbhag zero hai – standalone ₹2.0 Crore aur consolidated ₹9.4 Crore ke aas paas. Aur haath mein cash bhi tagda hai – standalone ₹169.4 Crore aur consolidated ₹139.1 Crore. Financial stability full hai!

Future Ka Vision: Global Player Banne Ka Plan!

Company ne FY26 se FY29 tak 35% ka mind-blowing CAGR revenue growth target rakha hai.

FY27 mein toh 40% se bhi zyada growth expect kar rahe hain!

Ye kaise hoga?

  • Egypt Plant: Q3 FY27 tak 60,000 MTPA ka ek naya manufacturing plant start hoga. Iske liye ₹70 Crore ka capex IPO funds se use kiya jayega. Ye plant sirf Egypt mein hi nahi, balki MENA, Europe aur USA mein bhi supply karega. Poora global market capture karne ka plan hai!
  • Palghar Facility: Ye naya facility Q1 FY27 tak full capacity mein operate karne lagega.
  • Company eco-friendly products launch karne par bhi focus kar rahi hai, jaise lead-free aur organic stabilizers, aur CPVC compounds.
  • Europe, USA aur MENA regions mein acquisitions (companies kharidna) bhi explore kar rahe hain.

Risks Ko Mat Bhoolna!

Sabse bada risk hai execution. Agar Egypt aur Palghar wale naye plants time pe aur budget mein start nahi hue toh growth targets miss ho sakte hain.

Naye plants aur products ke launch ke karan margins par thoda pressure ban sakta hai, khaas kar agar input costs badhe.

International markets mein jaane se geopolitical aur economic fluctuations ka risk badh jata hai.

Acquisitions bhi risky ho sakti hain, agar sahi company choose na karein ya integration mein problem aaye.

Investors Ke Liye Kya Dekhna Hai?

Ab sabki nazar rahegi ki Egypt aur Palghar wale plants time pe start hote hain ya nahi, aur kitni jaldi full capacity par chalta hain.

Kya company apna ambitious 40%+ growth target FY27 mein achieve kar pati hai aur 35% CAGR maintain karti hai, ye dekhna important hoga.

Aur sabse crucial: input costs manage karke margins ko kaise stable rakhte hain. Company ka global player banne ka safar kaise hota hai, ye sabse bada sawal hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.